ArticleRheumatology (Oxford, England)2026
Application of a novel Musculoskeletal Ultrasound Sum Score (MUSS) in the follow-up of patients with juvenile idiopathic arthritis.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThe objective of this study was to evaluate the novel Musculoskeletal Ultrasound Sum Score (MUSS) as a longitudinal marker of disease activity (DA) in patients with JIA within a treat-to-target management approach.
methodsDemographics, clinical, laboratory and US (B Mode, BM; Power Doppler Ultrasound, PDU; scored 0-3, using the paediatric OMERACT score) findings were recorded over a 1-year follow-up in the PRO-KIND cohort. The US imaging of joints was individual to the patient, determined by the treating clinicians (unaware of the study aims) as routine. MUSS (a combination of the highest single BM grade of all examined joints + the highest single PDU grade of all examined joints) was calculated (maximum score 6). Spearman correlations with clinical activity measures and ROC-derived MUSS cut-offs for clinical inactive disease were calculated, using pooled visit-level data.
resultsThirty-three JIA patients were included (oligoarthritis: n = 12, median age 4.4 years; polyarthritis: n = 21, 5.3 years). The median baseline MUSS was similar between subtypes. MUSS values decreased significantly over follow-up, paralleling improvements in JADAS-10 and global assessment scores. MUSS correlated strongly with JADAS-10, physician and parent/patient global scores (Ρ = 0.68-0.81; all P < 0.001) and with ESR in polyarthritis (Ρ = 0.57; P < 0.001). ROC analysis identified a MUSS cut-off of ≥1 as optimal for detecting active disease (specificity 100%, sensitivity 55%).
conclusionMUSS is a promising, feasible sonographic score for longitudinal monitoring of disease activity in JIA, showing strong correlations with clinical measures and excellent specificity for active disease at a cut-off of ≥1. Validation in independent, prospective cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.